Corum Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 7.50 Cr
as on 24-10-2024
- Paid Up Capital ₹ 6.00 Cr
as on 24-10-2024
- Company Age 20 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 7.15 Cr
as on 24-10-2024
- Satisfied Charges ₹ 4.25 Cr
as on 24-10-2024
- Revenue -1.71%
(FY 2023)
- Profit 9.69%
(FY 2023)
- Ebitda 71.30%
(FY 2023)
- Net Worth 3.58%
(FY 2023)
- Total Assets %
(FY 2023)
About Corum Lifesciences
The Corporate was formerly known as Northern Beverages (India) Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 7.50 Cr and a paid-up capital of Rs 6.00 Cr.
The company currently has active open charges totaling ₹7.15 Cr. The company has closed loans amounting to ₹4.25 Cr, as per Ministry of Corporate Affairs (MCA) records.
Khurram Malik and Saarah Khurram serve as directors at the Company.
- CIN/LLPIN
U50000UR2003PTC028174
- Company No.
028174
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Dec 2003
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Uttarakhand
Industry
Company Details
- Location
Haridwar, Uttarakhand, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Corum Lifesciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Khurram Malik  | Director | 30-Dec-2003 | Current |
| Saarah Khurram | Director | 02-May-2014 | Current |
Financial Performance of Corum Lifesciences.
Corum Lifesciences Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 1.71% decrease. The company also saw a slight improvement in profitability, with a 9.69% increase in profit. The company's net worth moved up by a moderate rise of 3.58%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Corum Lifesciences?
In 2023, Corum Lifesciences had a promoter holding of 40.00% and a public holding of 60.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Dena Bank Creation Date: 13 Jan 2015 | ₹7.15 Cr | Open |
Punjab National Bank Creation Date: 13 May 2014 | ₹3.50 Cr | Satisfied |
Canara Bank Creation Date: 28 Sep 2007 | ₹7.50 M | Satisfied |
How Many Employees Work at Corum Lifesciences?
Corum Lifesciences has a workforce of 0 employees as of Apr 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Corum Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Corum Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
